TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
TLSI 10.31.2024
Drug:TLSI-001 nelitolimod
Diseases:liver and pancreatic cancer
Date of Upcoming Event:2024-11-14
Name of Upcoming Event:TriSalus Life Sciences Conference Call
About Gravity Analytica
Call Scheduled for
The event will be webcast live on the investor relations section of TriSalus’ website athttps://investors.trisaluslifesci.com/news-events/events-presentations. A replay will also be available on the website following the event. Parties interested in participating by phone should register using thisonline form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin.
About
The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) approach to deliver a range of therapeutics: the TriNav®Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-OncologyTM (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD method are commonly present as well. Nelitolimod delivered by the PEDD method will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more attrisaluslifesci.comand follow us onX (formerly Twitter)andLinkedIn.
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031384321/en/
For Media Inquiries:
For Investor Inquiries:
Source: